视网膜静脉阻塞治疗市场 - 全球产业规模、份额、趋势、机会和预测，按疾病类型、治疗方法、最终用户区域和竞争细分，2020-2030 年预测

2024 年全球视网膜静脉阻塞治疗市场价值为 28.7 亿美元，预计到 2030 年将达到 42.6 亿美元，预测期内复合年增长率为 6.80%。全球视网膜静脉阻塞治疗市场是更广泛的医疗保健产业中一个充满活力且快速发展的产业。视网膜静脉阻塞 (RVO) 是一种常见的眼部血管疾病，如果不及时治疗，会导致视力障碍，因此成为患者和医疗保健专业人员关注的重大问题。随着全球老年人口不断增长，RVO 的盛行率不断上升，推动了对创新有效治疗方案的需求。

影响全球 RVO 治疗市场的关键因素包括医疗技术的进步、患者意识的提高以及研发活动的激增。製药公司积极致力于开发治疗 RVO 的新药物和疗法，重点是改善患者的治疗效果和生活品质。 RVO 治疗市场涵盖各种方法，包括药物介入、雷射治疗和外科手术。抗 VEGF（血管内皮生长因子）药物近年来作为有效的药物治疗选择而受到广泛关注，有助于减少 RVO 患者的水肿并改善视力。此外，在特定情况下，还可采用雷射治疗和手术介入来控制併发症或恢復受影响的视网膜静脉的血流。

主要市场驱动因素

老龄人口不断增加

主要市场挑战

治疗选择有限

主要市场趋势

药物治疗的进展

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球视网膜静脉阻塞治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疾病类型（视网膜中央静脉阻塞 (CRVO)、视网膜分支静脉阻塞 (BRVO)）
  • 依治疗（抗血管内皮生长因子 (Anti-VEGF)、皮质类固醇药物、其他）
  • 按最终用户（医院和诊所、零售药局、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 依疾病类型
  • 按治疗
  • 按最终用户
  • 按地区

第 5 章：亚太地区视网膜静脉阻塞治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疾病类型
  • 按治疗
  • 按最终用户
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 6 章：欧洲视网膜静脉阻塞治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美视网膜静脉阻塞治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲视网膜静脉阻塞治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲视网膜静脉阻塞治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 10 章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球视网膜静脉阻塞治疗市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

Global Retinal Vein Occlusion Treatment Market was valued at USD 2.87 billion in 2024 and is expected to reach USD 4.26 billion by 2030 with a CAGR of 6.80% during the forecast period. The global retinal vein occlusion treatment market is a dynamic and rapidly evolving sector within the broader healthcare industry. Retinal vein occlusion (RVO) is a common vascular disorder of the eye that can lead to vision impairment if left untreated, making it a significant concern for both patients and healthcare professionals. As the aging population continues to grow worldwide, the prevalence of RVO is on the rise, driving the demand for innovative and effective treatment options.

Key factors influencing the global RVO treatment market include advancements in medical technology, increasing awareness among patients, and a surge in research and development activities. Pharmaceutical companies are actively engaged in the development of novel drugs and therapies to address RVO, with a focus on improving patient outcomes and quality of life. The market for RVO treatment encompasses various approaches, including pharmacological interventions, laser therapy, and surgical procedures. Anti-VEGF (vascular endothelial growth factor) drugs have gained prominence in recent years as an effective pharmacological treatment option, helping to reduce edema and improve vision in RVO patients. Additionally, laser therapy and surgical interventions are utilized in specific cases to manage complications or restore blood flow in the affected retinal veins.

Key Market Drivers

Growing Aging Population

The aging population is a significant factor contributing to the growth of the global retinal vein occlusion (RVO) treatment market. As the world's demographic landscape undergoes a profound shift, with a substantial increase in the elderly population, the incidence of age-related eye conditions, such as RVO, is on the rise. RVO is notably more prevalent in individuals over the age of 50, making it a condition closely associated with the aging process. This demographic shift is driving demand for effective RVO treatments and significantly impacting the market in several ways.

According to WHO, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Key Market Challenges

Limited Treatment Options

The global retinal vein occlusion (RVO) treatment market faces a significant hurdle in the form of limited treatment options, which is hindering its growth and effectiveness. RVO is a vascular eye disorder that can result in vision impairment, and while there have been notable advances in treatment options, there remains a substantial portion of patients for whom the available treatments may be insufficient. This limitation poses a major challenge, as it leaves a significant portion of RVO patients without optimal solutions for their condition.

At present, the primary pharmacological approach to RVO treatment involves anti-vascular endothelial growth factor (anti-VEGF) drugs, which have shown efficacy in addressing macular edema and inflammation. However, these treatments are not universally effective, and there is a considerable variation in patient responses. Some individuals may experience minimal or no improvement, while others may require ongoing treatment that can be burdensome and uncomfortable. The inability to offer personalized, effective treatment options for all RVO patients hinders the market's ability to meet the diverse needs of

Key Market Trends

Advancements in Pharmacological Treatments

Advancements in pharmacological treatments have played a pivotal role in boosting the global retinal vein occlusion (RVO) treatment market. RVO, a vascular eye disorder that can lead to vision impairment, has seen remarkable progress in the development of novel therapies, particularly in the form of anti-vascular endothelial growth factor (anti-VEGF) drugs. These advancements have significantly improved the landscape of RVO treatment, offering patients more effective and convenient options for managing the condition.

Anti-VEGF drugs, such as aflibercept and ranibizumab, have emerged as the cornerstone of RVO treatment, primarily addressing RVO-related macular edema. These drugs work by inhibiting the growth of abnormal blood vessels in the retina, reducing inflammation, and preventing the leakage of fluid into the macula. The introduction of anti-VEGF treatments has revolutionized RVO management, offering patients a less invasive and more patient-friendly therapeutic approach. They have proven effective in reducing edema, improving visual outcomes, and preserving the patient's quality of life.

Key Market Players

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.

Report Scope:

In this report, the Global Retinal Vein Occlusion Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Retinal Vein Occlusion Treatment Market, By Disease Type:

• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Retinal Vein Occlusion Treatment Market, By Treatment:

• Anti-vascular Endothelial Growth Factor (Anti-VEGF)
• Corticosteroid Drugs
• Others

Retinal Vein Occlusion Treatment Market, By End-user:

• Fully Automated
• Semi-Automated
• Manual

Retinal Vein Occlusion Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Retinal Vein Occlusion Treatment Market.

Available Customizations:

Global Retinal Vein Occlusion Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Retinal Vein Occlusion Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO))
  • 4.2.2. By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Others)
  • 4.2.3. By End-user (Hospital & Clinics, Retail Pharmacy, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Disease Type
  • 4.3.2. By Treatment
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. Asia Pacific Retinal Vein Occlusion Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type
  • 5.2.2. By Treatment
  • 5.2.3. By End-user
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Disease Type
      • 5.3.1.2.2. By Treatment
      • 5.3.1.2.3. By End-user
  • 5.3.2. India Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Disease Type
      • 5.3.2.2.2. By Treatment
      • 5.3.2.2.3. By End-user
  • 5.3.3. Australia Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Disease Type
      • 5.3.3.2.2. By Treatment
      • 5.3.3.2.3. By End-user
  • 5.3.4. Japan Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Disease Type
      • 5.3.4.2.2. By Treatment
      • 5.3.4.2.3. By End-user
  • 5.3.5. South Korea Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Disease Type
      • 5.3.5.2.2. By Treatment
      • 5.3.5.2.3. By End-user

6. Europe Retinal Vein Occlusion Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment
  • 6.2.3. By End-user
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End-user
  • 6.3.2. Germany Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End-user
  • 6.3.3. Spain Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End-user
  • 6.3.4. Italy Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease Type
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By End-user
  • 6.3.5. United Kingdom Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease Type
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By End-user

7. North America Retinal Vein Occlusion Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment
  • 7.2.3. By End-user
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End-user
  • 7.3.2. Mexico Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End-user
  • 7.3.3. Canada Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End-user

8. South America Retinal Vein Occlusion Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End-user
  • 8.3.2. Argentina Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End-user
  • 8.3.3. Colombia Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End-user

9. Middle East and Africa Retinal Vein Occlusion Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment
  • 9.2.3. By End-user
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End-user
  • 9.3.2. Saudi Arabia Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End-user
  • 9.3.3. UAE Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End-user

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Retinal Vein Occlusion Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. AbbVie Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd.
• 14.3. Regeneron Pharmaceuticals Inc.
• 14.4. Taiwan Liposome Company, Ltd.
• 14.5. Aerie Pharmaceuticals Inc.
• 14.6. CalciMedica Inc.
• 14.7. Outlook Therapeutics, Inc.
• 14.8. Kodiak Sciences Inc.
• 14.9. Chugai Pharmaceutical Co., Ltd.
• 14.10.Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer